Celcuity Inc. (CELC) FY2024 10-K Annual Report
Celcuity Inc. (CELC) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 31, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Celcuity Inc. FY2024 10-K Analysis
Business Overview
- • Core business: Clinical-stage biotech developing gedatolisib, a pan-PI3K/mTOR inhibitor targeting multiple solid tumors, primarily HR+/HER2- advanced breast and metastatic prostate cancer
- • New emphasis: Initiation and enrollment updates for two Phase 3 trials (VIKTORIA-1 completed PIK3CA WT enrollment in Q4 2024; VIKTORIA-2 site activation in Q3 2024, first patient expected Q2 2025)
Management Discussion & Analysis
- • No revenue or profitability data disclosed in the provided text
- • No segment performance information available
Risk Factors
- • FDA approval risk tied to VIKTORIA-1 trial topline data expected Q2 2025, crucial for gedatolisib market authorization
- • Clinical trial site exposure: 200+ sites across North America, Europe, Latin America, Asia-Pacific for VIKTORIA-1 and VIKTORIA-2 trials
Celcuity Inc. FY2024 Key Financial MetricsXBRL
Net Income
-$112M
▼ -75.3% YoY
ROE
-96.7%
▼ -5105bp YoY
Total Assets
$245M
▲ +28.2% YoY
EPS (Diluted)
$-2.83
▼ -5.2% YoY
Operating Cash Flow
-$83M
▼ -55.1% YoY
Source: XBRL data from Celcuity Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Celcuity Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.